Autres langues MBX Biosciences, Inc.

Actions

MBX

US55287L1017

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/06/2026			Varia. 5j.	Varia. 1 janv.
40,09 ^USD	+2,85 %		+34,21 %	+27,11 %

12/06	Transcript : MBX Biosciences, Inc. - Special Call
12/06	L'essai de phase 2 de MBX Biosciences sur le canvuparatide atteint son critère d'évaluation principal ; le titre chute en avant-Bourse	MT

Autres langues

12/06	MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell
12/06	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
12/06	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential PTH Replacement Therapy In Chronic Hypoparathyroidism
01/06	MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
26/05	MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
11/05	Mbx Biosciences Insider Sold Shares Worth $2,685,515, According to a Recent SEC Filing
11/05	MBX Biosciences : May 2026 Obesity Day Presentation – Final
11/05	MBX Biosciences, Inc. Provides Obesity Portfolio Update Including Initial Phase 1 Data For MBX 4291 Supporting Potential For Once-Monthly Dosing
11/05	MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
08/05	Mbx Biosciences, Inc. Announces Resignation of Steven L. Hoerter from Audit Committee of the Board, Effective May 1, 2026
07/05	MBX Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	MBX Biosciences : Company Overview - May 2026
07/05	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
07/05	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
07/05	MBX Biosciences, Inc. Appoints Mark R. Soued as Chief Commercial Officer
23/04	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
22/04	PMV Pharmaceuticals, Inc. Announces Board Changes, Effective June 4, 2026
03/04	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16/03	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing
12/03	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
12/03	MBX Biosciences Q4 Net Loss Widens; Expects Cash Runway Into 2029
12/03	Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss
12/03	MBX Biosciences : Company Overview - March 2026
12/03	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
10/03	MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer